Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SAN ANTONIO, Nov. 15, 2016 -- bioAffinity Technologies announced that the government of the Hong Kong Special Administrative Region has awarded a Certificate of Grant of Standard Patent for the Company’s proprietary CyPath© technology for the early detection of lung cancer.
The Hong Kong patent, titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” grants protection to 2030 for bioAffinity’s platform test for early cancer detection. bioAffinity’s intellectual property (IP) portfolio now consists of 43 awarded patents in 22 countries.
bioAffinity’s porphyrin-based CyPath© bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence that is detectable and measurable by an imaging system. CyPath© Lung, bioAffinity’s initial product, is designed to be a highly accurate, non-invasive, early-stage lung cancer diagnostic for use by those at risk for lung cancer.
“Lung cancer is the leading cause of cancer deaths worldwide, and as much as 85 percent of lung cancers are attributable to smoking,” bioAffinity President and CEO Maria Zannes said. “With an estimated 370 million smokers in China, Hong Kong and Japan, our technology can have a significant positive impact on early detection and more effective treatment of the disease in Asia, the world’s largest market. We are pleased to add the Hong Kong patent to our existing patents in China and Japan.”
bioAffinity is focused on the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics for multiple cancers. CyPath© Lung is a simple and cost-effective diagnostic, which will make it particularly effective in countries with large populations and a broad demographic.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747
